A Phase 1b study of FIN-211 in children with autism spectrum disorder (ASD) and gastrointestinal symptoms
Latest Information Update: 02 Sep 2022
At a glance
- Drugs FIN-211 (Primary)
- Indications Gastrointestinal disorders; Pervasive child development disorders
- Focus Adverse reactions
- Acronyms AUSPIRE
- Sponsors Finch Therapeutics Group
- 01 Sep 2022 According to a Finch Therapeutics media release, the company have decided to suspend efforts to initiate this phase 1 trial while it will explore opportunities to leverage clinical data from ongoing third-party studies to inform our autism program strategy going forward.
- 16 May 2022 According to a Finch Therapeutics media release, company anticipates submitting the IND for FIN-211 in Q4 2022.
- 31 Mar 2022 According to a Finch Therapeutics Group media release, this trial will be delayed in connection with the clinical hold related to the IND for CP101.Finch is evaluating the extent of the expected delay to the timing of AUSPIRE and, based on manufacturing timelines, expects at least a one quarter delay.